Lilly’s Foundayo Quickly Gains Ground in the Oral Weight-Loss Market

Lilly’s Foundayo Quickly Gains Ground in the Oral Weight-Loss Market

Tue, September 15, 2026 at 5:42 PM GMT+3 5 min read

• LLY +0.69%
• NVO -1.65%

Eli Lilly and Company (NYSE:LLY) says its newly launched oral obesity drug Foundayo has captured more than 30% of new U.S. patients starting oral weight-loss medicines, a notable early gain against Novo Nordisk's Wegovy pill. Reuters reports that Wegovy initially held roughly 90% of the oral market, making Lilly's rapid share capture an important sign that the oral GLP-1 market is becoming a two-player competition rather than a Novo-dominated segment. The broader U.S. obesity-drug market is expected to exceed $100 billion annually by 2030, with oral treatments potentially accounting for more than one-third of GLP-1 use.

The timing is strategically important for Lilly because Foundayo was only launched in the U.S. in April 2026. The drug starts at $149 per month for self-pay patients and can cost as little as $25 for eligible commercially insured patients, while Medicare beneficiaries can access it through the GLP-1 Bridge program at $50 per month. Lilly's SEC filing says Mounjaro and Zepbound already represented 65% of its revenue in the first six months of 2026, highlighting both the importance of the incretin franchise and the opportunity for Foundayo to broaden Lilly's cardiometabolic revenue base.

Early Foundayo Momentum Could Extend Lilly's GLP-1 Leadership

The strongest bullish implication is that Foundayo appears to be overcoming the biggest behavioral barrier in obesity treatment: patients' preference for an oral medicine over an injection. Capturing more than 30% of new oral patients only months after launch suggests Eli Lilly and Company (NYSE:LLY) is establishing meaningful competitive positioning before the oral GLP-1 market fully scales. Foundayo's formulation also has a practical advantage because it can be taken at any time of day without food or water restrictions, while Lilly's clinical data showed an average 27.3-pound, or 12.4%, weight reduction at the highest dose among patients who remained on treatment in ATTAIN-1.

The commercial opportunity could become considerably larger if Foundayo gains indications beyond obesity. Lilly reported that in the ACHIEVE-3 trial, Foundayo produced a 57.1% greater relative reduction in A1C and a 73.6% greater relative reduction in body weight compared with oral semaglutide 14 mg. Lilly submitted Foundayo for type 2 diabetes in the U.S., EU, and Japan, potentially expanding the addressable market beyond weight management.

The early oral-market traction also complements Eli Lilly and Company (NYSE:LLY)'s existing injectable franchise rather than simply cannibalizing it. A Lilly trial found that patients switching from maximum-tolerated Wegovy to Foundayo maintained all but 0.9 kg of their previous weight loss after one year, while patients switching from maximum-dose Zepbound to Foundayo maintained all but 5.0 kg. That suggests Foundayo could serve as a maintenance or lower-burden treatment within Lilly's broader obesity portfolio, increasing lifetime value per patient rather than limiting the opportunity to new prescriptions.

Foundayo's Early Share Gain Faces Pricing and Competitive Risks

The key risk is that the reported 30%-plus share represents new patients in the oral category, not the overall obesity-drug market. Foundayo therefore still has to prove that its early prescription momentum can translate into sustained volume, long-term adherence, and meaningful revenue. Novo's Wegovy pill started with approximately 90% of new oral patients, so Eli Lilly and Company (NYSE:LLY)'s gain is encouraging, but the competitive landscape is changing rapidly, and Novo is already studying lower-dose versions of its pill that could improve affordability, tolerability and treatment flexibility.

Pricing could also pressure the economic value of the market as competition intensifies. Lilly has already introduced Foundayo at relatively low access prices, including $25 for some commercially insured patients and $50 through the Medicare Bridge program. If Lilly and Novo compete aggressively for share through discounts and payer concessions, prescription growth could translate into less revenue per patient and weaker margins than headline market-share figures imply. This matters because Lilly's own SEC filing says its near-term financial performance will depend partly on the pace of uptake in new incretin channels and markets, while Mounjaro and Zepbound already account for 65% of first-half revenue.

There is also a longer-term competitive risk from Lilly's own portfolio. Retatrutide, Lilly's next-generation triple agonist, produced average weight loss of 28.3% at 80 weeks in the pivotal TRIUMPH-1 trial, materially above Foundayo's 12.4% figure in ATTAIN-1. If retatrutide ultimately reaches the market, Lilly may have to balance Foundayo's role as an accessible oral treatment against a potentially much more efficacious next-generation therapy. At the same time, Novo remains a formidable competitor, and the obesity market is attracting additional pharmaceutical companies, increasing the probability of pricing and market-share pressure over time.

Conclusion

The news is net bullish for Eli Lilly and Company (NYSE:LLY) because Foundayo has rapidly secured more than 30% of new U.S. oral weight-loss patients despite entering a market initially dominated by Novo's Wegovy pill. The early share gain validates Lilly's oral strategy and could create a substantial second growth engine alongside Zepbound and Mounjaro, particularly if the diabetes indication expands Foundayo's addressable market.

However, investors should distinguish prescription share from profitable revenue growth: pricing pressure, Novo's response, patient persistence, and eventual competition from next-generation drugs such as retatrutide will determine how much of this early momentum translates into earnings and cash flow.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

READ NEXT: Abbott Faces $384 Million Cost as Infant Formula Legal Risks Persist and Bank of America Warns of 10%+ Drop in Q3 Investment Banking Fees

This article is originally published at Insider Monkey.